Skip to main content
Clinical Trials/CTRI/2024/05/067550
CTRI/2024/05/067550
Not yet recruiting
Phase 2

A comparative study to evaluate efficacy and safety of daily versus alternate day rosuvastatin therapy in patients with dyslipidemia - NI

George T Varghese0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: E785- Hyperlipidemia, unspecified
Sponsor
George T Varghese
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
George T Varghese

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients willing to give written informed consent.
  • 2\. Patients aged more than 18 and less than or equal to 65 years.
  • 3\. Treatment naive patients of dyslipidemia in low to moderate risk group as diagnosed by NCEP ATP III guidelines

Exclusion Criteria

  • 1\. Patients unwilling to give written informed consent.
  • 2\. Patients with a documented history of acute coronary syndrome, cerebrovascular accident, on\-going angina.
  • 3\. Pregnant and lactating mothers.
  • 4\. Patients on co\-existing medication which aggravate statin myopathy.

Outcomes

Primary Outcomes

Not specified

Similar Trials